Argenica Therapeutics : Investor Presentation

onlyuseARGENICATHERAPEUTICS ersonal1

J U N E 2 0 2 2

onlyuseARGENICATHERAPEUTICS ersonal2

This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the "Company") and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters: this presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

www.argenica.com.au

onlyuseARGENICATHERAPEUTICS ersonal3

Commercialise "best in class"		Neuroprotective peptide
novel neuroprotective
	that could offer protection to
therapeutics to reduce brain
	the brain following stroke and
cell death following stroke
	other acute central nervous
and other brain injuries
	system injuries

GRANTED PATENTS

Granted in the EU, Japan

China, and the US

FREE OF ENCUMBRANCES

IP 100% owned by Argenica and free of royalties or other encumbrances

www.argenica.com.au

onlyuseARGENICA THERAPEUTICS

ersonal

Total Shares on issue	86,922,250
Shares subject to escrow for 24 months 1	22,625,752
Options on issue (escrow for 24 months) 1 & 2	8,300,000
Options on issue (not escrowed) 3	1,700,000
Cash Balance 4	Circa $9.54M
Market Capitalisation @ $0.40 5	Circa $34.8M
Enterprise Value (EV) @ $0.40 5	Circa $25.2M

					Inventors and Research
					Team
	SHAREHOLDERS 6
	4.0%	4.5%	2.8%	12.3%		76.4%

Board, Management and Advisors

Other Shareholders

1.

2.

3.

4.

5.

6.

4

24 months from the date of commencement of Official Quotation on ASX - 11th June 2023 Option Terms - Ex price $0.30, expiry 30 Sept 2024

Option Terms - 800,000 Ex price $0.30, expiry 6 Aug 2023; 300,000 Ex price $1.10, expiry 1 Apr 2025; 600,000 Ex price $0.65, expiry 10 Jun 2024 As @ 31 March 2022 adjusted for $5.5m placement in Jun 2022 net of cash capital raising fees

Closing price as @ 8 Jun 2022

Percentages are estimates only and subject to slight variation

www.argenica.com.au

onlyuseARGENICATHERAPEUTICS ersonal5

Cell death in the brain, or infarction, results from inadequate blood supply to the affected area.

Initial infarction sets off a cascade of cell death.

While no drug can stop the initial infarct injury, ARG-007 has multiple mechanisms of action to stop the cascade of cell death that happens after the initial injury.

In animal models of stroke, ARG-007slowsthe progression of neuronal cell death and preserve still viable brain tissue.

This increases the amount of available salvageable brain tissue.

ISCHEMIC STROKE

EXAMPLE

BRAIN TISSUE DAMAGE

(INFARCT)

STOPS CASCADE OF CELL DEATH

www.argenica.com.au